Q-omics provides the consensus-scored SMG8 profile across patient tissues and cancer cell-line models. SMG8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMG8 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, SMG8 protein abundance shows 22,228 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KIRP, and LSCC as cancer lineages where SMG8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMG8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMG8 survival associations across molecular data types. SMG8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMG8 RNA expression–survival associations across cancer types. High SMG8 expression shows unfavorable associations in LIHC, CESC, BLCA and KICH, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMG8 RNA expression.
This table summarizes SMG8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMG8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMG8 shows lower tumor expression in THCA and higher tumor expression in KIRP, HNSC, KIRC, LUAD and BLCA. The KIRP box plot shows higher SMG8 RNA expression in tumor versus normal tissue (log2 FC = +1.151, t-test p < 0.001).
This table shows molecular features associated with SMG8 in patient tissues and cancer cell lines. In patient samples, SMG8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMG8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
